As of the latest Form 4 filed May 29, 2026.
What Kyverna Therapeutics, Inc. Common Stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 12 most recent filings for KYTX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | 2026-05-27 | CLARK IAN T Director | AAward | +5.09K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-29 | 2026-05-27 | Cohen Fred E Director | AAward | +5.09K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-29 | 2026-05-27 | SEIDENBERG BETH C Director | AAward | +5.09K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-29 | 2026-05-27 | Shaw Christi Executive Chairperson | FTax | −4.19K | $8.59 | $36.0K | No | Form 4 ↗ |
| 2026-05-29 | 2026-05-27 | Aktar Mert Director | AAward | +5.09K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Emany Sravan Kumar Director | AAward | +11.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-12 | Shaw Christi Executive Chairperson | AAward | +24.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-12 | Shaw Christi, Executive Chairperson | AAward | +30.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-22 | 2025-12-18 | SEIDENBERG BETH C Director | PPurchase | +133K | $7.50 | $1000K | No | Form 4 ↗ |
| 2025-12-22 | 2025-12-18 | Westlake BioPartners Opportunity Fund I, L.P. 10% owner | PPurchase | +133K | $7.50 | $1000K | No | Form 4 ↗ |
| 2025-12-17 | 2025-12-15 | Walker Karen Marie Chief Technology Officer | SSale | −24.0K | $12.20 | $293K | Yes (planned) | Form 4 ↗ |
| 2025-12-17 | 2025-12-15 | Walker Karen Marie, Chief Technology Officer | MExercise | +24.0K | $4.83 | $116K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also KYTX’s full analysis or the market-wide insider trading feed. The tabs above jump to KYTX’s other SEC data.
Source: SEC Form 4 filings for KYTX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.